Author Archive: BIOtechNOW Editor

BIO Innovation Zone Company Snapshots: Iron Horse Diagnostics and Nimbic Systems

BIO Innovation Zone

This week in Philadelphia at the BIO International Convention, BIO is partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone, which opens tomorrow, will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies. The SBIR/STTR program provides U.S. federal funding to small businesses engaged in research with the potential for commercialization. Each of the companies has been rigorously vetted through the SBIR/STTR review process Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Innovation Zone Company Snapshots: Aciont Inc. and TF Health Co.

BIO Innovation Zone

This week in Philadelphia at the BIO International Convention, BIO is partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone, which opens tomorrow, will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies. The SBIR/STTR program provides U.S. federal funding to small businesses engaged in research with the potential for commercialization. Each of the companies has been rigorously vetted through the SBIR/STTR review process Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

JPM-MCS and Industry Day

jpm-mcs_medical-countermeasure_systems

The Joint Project Manager for Medical Countermeasure Systems (JPM-MCS), a program within the Department of Defense (DoD), is coming to the 2015 BIO International Convention with a mission: to find new ways to work with the private sector to combat chemical and biological threats. JPM-MCS provides U.S. military forces — and the nation — with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear (CBRN) threats. This program plays a vital Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Is Almost Here – What To Consider Before Entering New Therapeutic Areas

BIO International Convention

Over the past decade, the biopharmaceutical industry has witnessed a shift towards specialty care. From 2008 to 2014, FDA specialty drug approvals jumped from 33 percent to over 50 percent of all approvals. In 2014, the FDA approved a record 19 specialty care medicines. Given this new reality, companies are expanding the focus of their R&D into new therapeutic areas to address difficult-to-treat, specialty care conditions. Building successful franchises requires a strategic approach to determine the Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Life Science Leader Asks: What Biopharma Trends Should Pharma Execs Be Paying Attention To?

Life Science Leader

In my last installment of this four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas & Associates, I asked what trends should biopharma execs be paying greater attention to and why. Check out my interview to get insights from Peter on upcoming trends! Peter’s session, Inventing Your Own Hub: Evolving Institutional Models for Translational Medicine, will be taking plan June 16 from 3:30 p.m.-4:45 p.m. in room 105AB. If you missed the earlier segments in this series, here is Part 1, Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,